Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flurbiprofen axetil + fentanyl + midazolam
- Development stage
- Unknown
- Lead developer
- Beijing An Zhen Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
flurbiprofen axetil + fentanyl + midazolam is a combination sedation and analgesic regimen developed by Beijing Anzhen Hospital for use in patients undergoing pulsed-field ablation (PFA) for atrial fibrillation. This protocol, referred to as the Enhanced Analgesia Group (DS2) in the DEEP-PFA clinical trial, combines the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen axetil, the potent opioid analgesic fentanyl, and the benzodiazepine sedative midazolam. Flurbiprofen axetil acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis. Fentanyl is a highly potent mu-opioid receptor agonist providing rapid-onset analgesia. Midazolam acts as a positive allosteric modulator of the GABA-A receptor, providing sedation and anxiolysis. The combination is designed to provide deep sedation without the need for airway assistance during cardiac ablation procedures.
- Other names
- Enhanced Analgesia Group
02
Targets
MOR (Mu opioid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABAA (Gamma-aminobutyric acid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on flurbiprofen axetil + fentanyl + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flurbiprofen axetil + fentanyl + midazolam.